The Montes Claros site in Brazil is just one of many that Novo Nordisk has poured billions of dollars into as part of efforts to scale manufacturing capabilities. There was also the $16.5bn ...

The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Pharmaceutical company Novo Nordisk will expand its production site in Montes Claros, Brazil, creating 600 jobs.

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for its weight loss drugs Wegovy and Ozempic. These drugs continue to be the ...

Novo Nordisk (NVO) is not a stock that is constantly ... patents expiring in some regions of the world such as Brazil, and these uncertainties in important markets for the company, such as North ...

Wall Street on Friday overcame a volatile morning trading session to push higher, ending a wild week on a positive note. Tariffs dominated headlines, with the latest being that the Trump ...